European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
July 17, 2026
Mauro Scala, Enrico Magrini, Ivana Leccisotti et al.
Suicide remains a leading cause of premature mortality worldwide. Current treatments are limited by delayed onset, durability, or poor tolerability. This narrative review, informed by a structured literature search, summarises the last decade of evidence on pharmacological and neuromodulation interventions for suicidal ideation (SI) or suicide attempt (SA) that are not approved for these...
Journal of psychopharmacology (Oxford, England)
April 24, 2026
Marco Colizzi, Elisa Morandin, Veronica Croccia et al.
Interleukin-6 (IL-6) has been implicated as a potential predictor of ketamine response in treatment-resistant depression (TRD). Esketamine, the S-enantiomer of ketamine, produces rapid antidepressant effects and offers improved safety and intranasal administration. To examine whether baseline IL-6 predicts treatment response to esketamine in individuals with TRD. Fourteen adults with TRD...
Healthcare
August 16, 2022
Riccardo Bortoletto, Marco Colizzi
Being particularly vulnerable to the pro-psychotic effects of cannabinoid exposure, autism spectrum individuals present with an increased risk of psychosis, which may be passed on to their own children. More specifically, cannabis exposure among autism spectrum individuals seems to exert disruptive epigenetic effects that can be intergenerationally inherited in brain areas which play a critical...
Frontiers in Psychology
May 14, 2020
Marco Colizzi, Mirella Ruggeri, Sagnik Bhattacharyya
50 citations
Research evidence suggests a dose-response relationship for the association between cannabis use and risk of psychosis. Such relationship seems to reflect not only an increased risk of psychosis as a function of frequent cannabis use, but also of high-potency cannabis use in terms of concentration of delta-9-tetrahydrocannabinol (∆9-THC), its main psychoactive component. This finding would be...
Brain Sciences
February 27, 2020
Marco Colizzi, Sarah Tosato, Mirella Ruggeri
Several studies have advanced the understanding of the effects of cannabis on cognitive function. A comprehensive reappraisal of such literature may help in drawing conclusions about the potential risks associated with cannabis use. In summary, the evidence suggests that earlier age of use, high-frequency and high-potency cannabis use, as well as sustained use over time and use of synthetic...
2020
Marco Colizzi, Sagnik Bhattacharyya
Abstract Accumulating evidence suggests an association between cannabis use and psychosis. However, some concerns have been raised about the nature of this association, particularly whether it might be driven by other factors such as use of other substances. Another explanation would bring into play preexisting differences among cannabis users and nonusers in terms of psychosis-related...
European Neuropsychopharmacology
July 1, 2018
Marco Colizzi, P. McGuire, Vincent Giampietro et al.
Cannabis use has been associated with psychosis and cognitive dysfunction. Some evidence suggests that the acute behavioral and neurocognitive effects of the main active ingredient in cannabis, (-)-trans-Δ9-tetrahydrocannabinol (∆9-THC), might be modulated by previous cannabis exposure. However, this has not been investigated either using a control group of non-users, or following abstinence in...
Current Addiction Report
April 29, 2017
Marco Colizzi, Sagnik Bhattacharyya
Purpose of ReviewThe lack of clarity about the effect of cannabis use on cognition may be attributable to the considerable heterogeneity among studies in terms of cannabis composition. This article selectively reviews studies examining the distinctive effects of cannabinoids on human cognition, particularly those of delta-9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD).Recent...